CASI Pharmaceuticals, Inc.

CASI • Biotechnology

$0.15

— 0.00 (0.00%)

EarningsLatest report: Sep 30, 2025

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$2.42M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Positive revenue growth · 7.9%High debt level · 11.96Weak profitability

Financial data as of: Sep 30, 2025, 12:00 AM UTCLast earnings update: Nov 14, 2025, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.15

Change0.00%

Shares Out16.05M

Market Cap$2.42M

Enterprise Value$16.59M

52W Range0.14 - 3.09

Beta0.89

P/E-0.05

P/S0.09

P/B-0.08

EV/Sales0.62

EV/EBITDA-0.40

Price$0.15

Change0.00%

Shares Out16.05M

Market Cap$2.42M

Enterprise Value$16.59M

52W Range0.14 - 3.09

Beta0.89

P/E-0.05

P/S0.09

P/B-0.08

EV/Sales0.62

EV/EBITDA-0.40

FCF Yield0.00%

Dividend Yield0.00%

Gross Margin39.06%

Oper. Margin-138.84%

Profit Margin-137.57%

Debt/Eq11.96

Current Ratio1.09

Quick Ratio0.94

Target$6.00

Target Upside3886.71%

Target Median$6.00

Target Range6.00 - 6.00

Volume7.90K

Avg Volume225.20K

EPS Surprise-0.27

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

38/100

Growth Potential

Revenue and expansion

85/100

Price Attractiveness

Cheap or expensive today

55/100

Why this score▼

Positive revenue growth · 7.9%High debt level · 11.96Weak profitability

Analyst view

Analyst sentiment and price target

CASI

Analyst sentiment

Based on 6 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Price Target

2026-06-30

Low

$6.00

Mean

$6.00

Median

$6.00

High

$6.00

Company Overview

IPO: 6/12/1996

Industry: Biotechnology

P/B i: -0.08

Debt / Equity i: 11.96

Operating Margin: -138.84%

Net Margin: -137.57%

ROE i: -

ROIC: -

Financial Health

Score8 / 20

Debt / Equity: 11.96

Current Ratio: 1.09

Quick Ratio: 0.94

Status: Moderate

Warnings

High debt level

Insider Transactions

Recent executive and insider activity

Huang James

Transaction: 03/18/2026

OTHER

Change

+101,571

Price

$1.93

Filing

03/18/2026

Type

OTHER

Huang James

Transaction: 03/18/2026

OTHER

Change

Price

Not reported

Filing

03/18/2026

Type

OTHER

Insider	Type	Change	Price	Transaction	Filing
Huang James	OTHER	+101,571	$1.93	03/18/2026	03/18/2026
Huang James	OTHER	0	Not reported	03/18/2026	03/18/2026

About the Company

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and market introduction of medical treatments and drugs across China, the United States, and globally. Its marketed product, EVOMELA, is an intravenous formulation of melphalan, utilized for conditioning prior to stem cell transplantation and as a palliative option for patients suffering from multiple myeloma. The company's developmental pipeline encompasses several experimental therapies. This includes CNCT19, an investigational autologous CD19 CAR-T therapy aimed at treating patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). BI-1206 is currently in Phase I/II trials, combined with the anti-PD1 therapy Keytruda, for solid tumors, and is also undergoing a Phase I/IIa study in conjunction with MabThera (rituximab) for individuals with relapsed/refractory NHL. CB-5339 is advancing through Phase I clinical trials for acute myeloid leukemia and myelodysplastic syndrome. Further additions to its pipeline are CID-103, targeting multiple myeloma patients, and Thiotepa, which possesses a broad range of indications, including its use as a conditioning therapy for various allogeneic hematopoietic stem cell transplants. Additionally, long-acting injectable formulations of Octreotide are being developed for managing acromegaly and alleviating symptoms associated with different neuroendocrine tumors. CASI maintains licensing agreements with Juventas Cell Therapy Ltd, BioInvent International AB, Black Belt Therapeutics Limited, and Cleave Therapeutics, Inc. It has also forged distribution partnerships with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd, Pharmathen Global BV, and Riemser Pharma GmbH. Incorporated in 1991, this Rockville, Maryland-based company was formerly known as EntreMed, Inc. before adopting its current name, CASI Pharmaceuticals, Inc., in June 2014.

Source - link

Peers

ALLR CING CLSD CRIS ENTO KAPA LSTA NCNA PALI PTHS

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results

SOUTH SAN FRANCISCO, CA / ACCESS Newswire / August 14, 2026 / CASI Pharmaceuticals, Inc. (OTCQB:CASIF), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with antibody-mediated rejection (AMR) in organ transplant and various autoimmune diseases, today reported business and financial results for the first half year ended June 30, 2026. "We remained focused on advancing the development of our lead program, CID-103," said Dr. Wei-Wu He, Executive Chairman and Principal Executive Officer of CASI.

Accesswire

Earnings Surprises

Period	Estimate	Actual	Surprise
2025-11-14	-0.4	-0.67	-0.27
2025-08-29	-0.47	-0.86	-0.39
2025-05-16	-0.61	-0.69	-0.08
2025-03-31	-0.6	-0.79	-0.19
2024-11-15	-0.62	-0.55	0.07
2024-08-16	-0.63	-0.52	0.11
2024-05-14	-0.05	-0.71	-0.66
2024-03-28	-0.24	-0.29	-0.05
2023-11-14	-0.56	-0.35	0.21
2023-08-11	-0.5	-0.77	-0.27
2023-04-26	-0.64	-1.44	-0.8
2023-03-29	-0.37	-0.4	-0.03